Core Viewpoint - 康希诺生物 reported a significant turnaround in its financial performance for the first three quarters, achieving a revenue increase and a shift from loss to profit [1] Financial Performance - For the nine months ending September 30, 2025, 康希诺生物 achieved a revenue of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to shareholders was 14.44 million yuan, compared to a net loss of 222 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.06 yuan [1] Industry Engagement - 康希诺生物 will participate in the world's largest pharmaceutical industry exhibition, CPHI Europe 2025, taking place in Frankfurt, Germany from October 28 to 30 [1] - The company plans to showcase its extensive product line, highlighting innovations in pneumonia vaccines, meningitis vaccines, and combined DTP vaccines, emphasizing its strengths and deep expertise in these key areas [1] - 康希诺生物 aims to initiate innovative collaborations and business expansion in the global vaccine Contract Research, Development, and Manufacturing Organization (CRDMO) sector [1]

Core Viewpoint - 康希诺生物 reported a significant turnaround in its financial performance for the first three quarters, achieving a revenue increase and a return to profitability [1] Financial Performance - For the nine months ending September 30, 2025, 康希诺生物 achieved a revenue of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to shareholders was 14.44 million yuan, a recovery from a net loss of 222 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.06 yuan [1] Industry Engagement - 康希诺生物 will participate in the CPHI Europe 2025, the largest pharmaceutical industry exhibition, taking place in Frankfurt, Germany from October 28 to 30 [1] - The company plans to showcase its extensive product line, highlighting innovations in pneumonia vaccines, meningitis vaccines, and combined DTP vaccines, emphasizing its strengths and deep expertise in these key areas [1] - 康希诺生物 aims to initiate innovative collaborations and business expansion in the global vaccine Contract Research, Development, and Manufacturing Organization (CRDMO) sector [1]